Cargando…

FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research—a systematic review and meta-analysis

BACKGROUND: FMS-like tyrosine kinase 3 (FLT3) is the most frequent mutation in AML. With two FLT3 inhibitors recently approved by the FDA (midostaurin and gilteritinib), there is a need to evaluate these targeted agents. PURPOSE: To assess the clinical effectiveness of FLT3 inhibitors in AML patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Majothi, S., Adams, D., Loke, J., Stevens, S. P., Wheatley, K., Wilson, J. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722339/ https://www.ncbi.nlm.nih.gov/pubmed/33287892 http://dx.doi.org/10.1186/s13643-020-01540-1

Ejemplares similares

Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia
por: Loke, J., et al.
Publicado: (2014)

Combination strategies to overcome drug resistance in FLT(+) acute myeloid leukaemia
por: Yang, Jingmei, et al.
Publicado: (2023)

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
por: Murray, Heather C., et al.
Publicado: (2020)

Computer simulations of the signalling network in FLT3 (+)-acute myeloid leukaemia – indications for an optimal dosage of inhibitors against FLT3 and CDK6
por: Buetti-Dinh, Antoine, et al.
Publicado: (2018)

Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2019)

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia
por: Park, Jung Eun, et al.
Publicado: (2013)

Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia
por: Wang, Hanlin, et al.
Publicado: (2023)

Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia
por: Finnon, R, et al.
Publicado: (2012)

FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation
por: Engen, Caroline, et al.
Publicado: (2021)

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
por: Steegmann, J L, et al.
Publicado: (2016)

FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018)

Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis
por: Hellesøy, Monica, et al.
Publicado: (2021)

Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia
por: Jensen, Christopher E., et al.
Publicado: (2022)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
por: Sorcini, D, et al.
Publicado: (2023)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations
por: Weisberg, Ellen, et al.
Publicado: (2020)

Novel Approaches to Target Mutant FLT3 Leukaemia
por: Müller, Jörg P., et al.
Publicado: (2020)

Clinico-Haematologic association and prognostic relevance of NPM1 and FLT3-ITD mutations in acute Myeloid Leukaemia
por: Mahmood, Rafia, et al.
Publicado: (2019)

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
por: Scholl, Sebastian, et al.
Publicado: (2020)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
por: Knight, Tristan E., et al.
Publicado: (2022)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)

Clinical use of FLT3 inhibitors in acute myeloid leukemia
por: Sutamtewagul, Grerk, et al.
Publicado: (2018)

FLT3 inhibitors: clinical potential in acute myeloid leukemia
por: Hospital, Marie-Anne, et al.
Publicado: (2017)

Developments and challenges of FLT3 inhibitors in acute myeloid leukemia
por: Ge, Shuai-Shuai, et al.
Publicado: (2022)

Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
por: Moore, Andrew S., et al.
Publicado: (2012)

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
por: Martínez-Cuadrón, David, et al.
Publicado: (2020)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
por: Mohanavelu, Prahathishree, et al.
Publicado: (2021)

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
por: Eguchi, Motoki, et al.
Publicado: (2020)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia
por: Song, Moo-Kon, et al.
Publicado: (2022)

The value of molecular stratification for CEBPA (DM) and NPM1 (MUT) FLT3 (WT) genotypes in older patients with acute myeloid leukaemia
por: Dickson, Glenda J., et al.
Publicado: (2015)

Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era
por: Choi, Sujin, et al.
Publicado: (2020)

Outcomes of Patients with FLT3 Positive Acute Myeloid Leukaemia; an Experience from a Tertiary Care Hospital in Karachi, Pakistan
por: Zulfiqar, Maria, et al.
Publicado: (2023)

Immunotherapy of acute myeloid leukaemia. Medical Research Council.
Publicado: (1978)

Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service
por: Othman, Jad, et al.
Publicado: (2021)

A Case of Myeloid Leukæmia
por: Ghosal, J. N.
Publicado: (1931)

Desacetylmethylcolchicine in the Treatment of Myeloid Leukaemia
por: Jelliffe, A. M., et al.
Publicado: (1956)

Cannot write session to /tmp/vufind_sessions/sess_4tjhseqoe1vhnpn71c29r4ups9